Following recent FDA clearance of NeoNavia, NeoDynamics announces US launch with its accompanying FlexiPulse™probe
Stockholm, Sweden, October 25, 2022 NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, announced today that it is launching the NeoNavia biopsy system configured with its FlexiPulse probe in the United States to support the diagnosis of cancer.
“The recent FDA clearance of the NeoNavia will help clinicians address the critical issues they face in diagnosing and treating breast cancer, which are the proper detection of cancerous tumors in the breast and its spread beyond”, said Anna Eriksrud, CEO of NeoDynamics. She continued, “The US breast biopsy market is expected to reach $830mm by 2025. As we bring this much needed diagnostic product to market, there is enormous value to clinicians, patients, and all stakeholders of NeoDynamics.”
Approximately one third of breast tumors need evaluation for metastatic cancer. Many of these patients undergo surgical removal of lymph nodes in the axilla (armpit). Surgical removal of axillary lymph nodes is often associated with delayed diagnosis due to the time needed to schedule an operating room, surgeon, anesthesiologist, and nurses, the high cost of the procedure, and the side effects such as swelling in the arms or chest wall due to lymphedema.
The FlexiPulse probe is developed for biopsies in challenging locations such as the axillary lymph nodes. Guided by ultrasound and powered by pneumatic pulses that move the probe millimeter by millimeter, it allows for high precision and control during needle insertion. An open-tip probe combined with pulses ensure that the surgeon or radiologist can safely maneuver the probe to obtain a high-quality tissue sample.
NeoNavia is designed to be the optimal tool to perform both the breast and axillary biopsy during a single patient visit with one system.
The US launch of the NeoNavia biopsy system with the FlexiPulse probe is scheduled for January 2023.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444 966 or e-mail firstname.lastname@example.org
Aaron Wong, CFO NeoDynamics AB, phone +46 735 972 011 or e-mail email@example.com
Tim Ryan, The Shoreham Group, US Investor Relations, phone +1 646 342 6199 or e-mail firstname.lastname@example.org
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and will soon launch in the USA. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
NeoNavia is a modern biopsy system with a completely new patented pulse technology intended for ultrasound-guided tissue sampling. Each needle type is driven by the pulse technology providing a more controlled needle insertion and precise placement of the needle in the tumor whilst enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.